 |
 |
| Comparisons of Indications and Adult Dosages | ||||||||||||||
| ACE I and II Inhibitors | ||||||||||||||
| Drug | Hypertension | CHF | Renal Dysfunction | Dialyzable | Strengths (mg) | |||||||||
| Benazepril (Lotensin®) | 10-40 mg/day | LV dysfunction (post-MI): 20-40 mg/day in 1-2 divided doses | Clcr <30 mL/min: 5 mg/day initially Maximum: 40 mg qd | Yes | Tablets 5, 10, 20, 40 | |||||||||
| Candesartan1 (Atacand®) | 4-32 mg qd qd-bid Maximum: 32 mg qd | Not FDA approved | No adjustment necessary | No | Tablets 4, 8, 16, 32 | |||||||||
| Captopril (Capoten®) | 25-150 mg qd bid-tid Maximum: 450 mg qd | 6.25-100 mg tid Maximum: 450 mg qd | Clcr 10-50 mL/min: 75% of usual dose Clcr <10 mL/min: 50% of usual dose | Yes | Tablets 12.5, 25, 50, 100 | |||||||||
| Enalapril (Vasotec®) | 5-40 mg qd qd-bid Maximum: 40 mg qd | 2.5-20 mg bid Maximum: 20 mg bid | Clcr 30-80 mL/min: 5 mg/day initially Clcr <30 mL/min: 2.5 mg/day initially | Yes | Tablets 2.5, 5, 10, 20 | |||||||||
| Enalaprilat2 | 0.625 mg, 1.25 mg, 2.5 mg q6h Maximum: 5 mg q6h | Not FDA approved | Clcr <30 mL/min: 0.625 mg | Yes | 2.5 mg/2 mL vial | |||||||||
| Eprosartan1 (Teveten®) | 400-800 mg qd qd-bid | Not FDA approved | No dosage adjustment necessary | Unknown | Tablets 400, 600 | |||||||||
| Fosinopril (Monopril®) | 10-40 mg qd Maximum: 80 mg qd | 10-40 mg qd | No dosage reduction necessary | Not well dialyzed | Tablets 10, 20, 40 | |||||||||
| Irbesartan1 (Avapro®) | 150 mg qd Maximum: 300 mg qd | Not FDA approved | No dosage reduction necessary | No | Tablets 75, 150, 300 | |||||||||
| Lisinopril (Prinivil®, Zestril®) | 10-40 mg qd Maximum: 40 mg qd | 5-40 mg qd | Clcr 10-30 mL/min: 5 mg/day initially Clcr <10 mL/min: 2.5 mg/day initially | Yes | Tablets 2.5, 5, 10, 20, 30, 40 | |||||||||
| Losartan1 (Cozaar®) | 25-100 mg qd or bid | Not FDA approved | No adjustment necessary | No | Tablets 25, 50, 100 | |||||||||
| Moexipril (Univasc®) | 7.5-30 mg qd qd-bid Maximum: 30 mg qd | Not FDA approved | Clcr <30 mL/min: 3.75 mg/day initially Maximum: 15 mg/day | Unknown | Tablets 7.5, 15 | |||||||||
| Olmesartan (BenicarTM) | 5-40 mg qd | Not FDA approved | No adjustment necessary | Unknown | Tablets 5, 20, 40 | |||||||||
| Perindopril (Aceon®) | 4-16 mg qd | 4 mg qd | Clcr 30-60 mL/min: 2 mg qd Clcr 15-29 mL/min: 2 mg qod Clcr <15 mL/min: 2 mg on dialysis days | Yes | Tablets 2, 4, 8 | |||||||||
| Quinapril (Accupril®) | 10-80 mg qd qd-bid | 5-20 mg bid | Clcr 30-60 mL/min: 5 mg/day initially Clcr <10 mL/min: 2.5 mg qd initially | Not well dialyzed | Tablets 5, 10, 20, 40 | |||||||||
| Ramipril (AltaceTM) | 2.5-20 mg qd qd-bid | 2.5-10 mg qd | Clcr <40 mL/min: 1.25 mg/day Maximum: 5 mg qd | Unknown | Capsules 1.25, 2.5, 5, 10 | |||||||||
| Telmisartan1 (Micardis®) | 20-80 mg qd | Not FDA approved | No dosage reduction necessary | No | Tablets 20, 40, 80 | |||||||||
| Trandolapril (Mavik®) | 2-4 mg qd Maximum: 8 mg/d qd-bid | LV dysfunction (post-MI): 1-4 mg qd | Clcr <30 mL/min: 0.5 mg/day initially | No | Tablets 1 mg, 2 mg, 4 mg | |||||||||
| Valsartan1 (Diovan®) | 80-160 mg qd Maximum: 320 mg/day | 40-160 mg bid | Decrease dose only if Clcr <10 mL/minute | No | Tablets 80, 160, 320 | |||||||||
| Dosage is based on 70 kg adult with normal hepatic and renal function. | ||||||||||||||
| 1Angiotensin II antagonist. | ||||||||||||||
| 2Enalaprilat is the only available ACE inhibitor in a parenteral formulation. | ||||||||||||||
| Return to Main Index | ||||||||||||||
|
||||||||||||||